oxazoles has been researched along with pa 824 in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (20.83) | 29.6817 |
| 2010's | 14 (58.33) | 24.3611 |
| 2020's | 5 (20.83) | 2.80 |
| Authors | Studies |
|---|---|
| Anderson, SW; Arain, TM; Baker, WR; Barry, CE; Kreiswirth, BN; Langhorne, MH; McMurray, DN; Sherman, DR; Stover, CK; Towell, JA; VanDevanter, DR; Warrener, P; Yuan, Y | 1 |
| Zhang, Y | 1 |
| Barry, CE; Dowd, CS; Goodwin, MB; Keller, TH; Knox, JE; Li, X; Lipinski, CA; Manjunatha, UH | 1 |
| Nau, JY | 1 |
| Mancera, RL; Rivers, EC | 1 |
| Barry, CE; Boshoff, HI; Cherian, J; Dick, T; Dowd, CS; Gurumurthy, M; Lee, YS; Manjunatha, UH; Mukherjee, T; Nayyar, A; Niyomrattanakit, P; Singh, R; Tay, JA | 1 |
| Jeong, BH; Koh, WJ; Kwon, YS | 1 |
| Cho, S; Franzblau, SG; Kim, Y; Lu, Y; Ma, Z; Mdluli, K; Upton, AM; Wang, B; Wang, Y; Xu, J; Yang, TJ | 1 |
| Amoabeng, O; Mdluli, KE; Minkowski, A; Nuermberger, EL; Tasneen, R; Upton, AM; Williams, K | 1 |
| Chang, KC; Heyckendorf, J; Lange, C; Olaru, ID; von Groote-Bidlingmaier, F; Yew, WW | 1 |
| Blaser, A; Denny, WA; Franzblau, SG; Kmentova, I; Ma, Z; Palmer, BD; Sutherland, HS; Thompson, AM; Wan, B; Wang, Y | 1 |
| Betoudji, F; Converse, PJ; Dartois, V; Li, SY; Mdluli, KE; Mendel, CM; Nuermberger, EL; Tasneen, R; Tyagi, S; Williams, K; Yang, T | 1 |
| Anderson, RF; Blaser, A; Chatelain, E; Denny, WA; Franzblau, SG; Launay, D; Ma, Z; Maes, L; Palmer, BD; Shinde, SS; Thompson, AM; Wan, B; Wang, Y | 1 |
| Ahmed, Z; Bhagat, A; Kour, G; Singh, PP | 1 |
| Arbex, MA; D'Ambrosio, L; Dalcolmo, M; Duarte, R; Gaga, M; Migliori, GB; Munoz-Torrico, M; Rendon, A; Silva, DR; Tiberi, S; Visca, D; Zumla, A | 1 |
| Loganathan, U; Mukhopadhyay, B; Purwantini, E | 1 |
| Laughon, BE; Lee, SFK; Lipman, M; McHugh, TD | 1 |
| Ceyssens, PJ; Coppee, JY; Legendre, R; Mathys, V; Sismeiro, O; Sury, A; Van den Bossche, A; Varet, H | 1 |
| Dheda, K; Dooley, KE; Furin, J; Gumbo, T; Maartens, G; Murray, M; Nardell, EA; Warren, RM | 1 |
| Afriat-Jurnou, L; Ahmed, FH; Almeida, DV; Aung, HL; Beatson, SA; Cook, GM; Forde, BM; Greening, C; Hards, K; Harold, LK; Jackson, CJ; Lee, BM; Mohamed, AE; Nuermberger, EL; Pidot, SJ; Stinear, TP; Taylor, MC; West, NP | 1 |
| Farhat, M; Kadura, S; King, N; Köser, CU; Nakhoul, M; Theron, G; Zhu, H | 1 |
| Bashiri, G; Ioerger, T; Lanoix, JP; Lee, J; Li, SY; Nuermberger, E; Rifat, D; Sacchettini, J; Shah, K | 1 |
| Campino, S; Clark, TG; Gomes, P; Gómez-González, PJ; Hibberd, ML; Napier, G; Perdigao, J; Phelan, JE; Portugal, I; Puyen, ZM; Santos-Lazaro, D; Viveiros, M | 1 |
| Bax, HI; De Steenwinkel, JEM; Lenaerts, A; Mudde, SE; Upton, AM | 1 |
8 review(s) available for oxazoles and pa 824
| Article | Year |
|---|---|
Advances in the treatment of tuberculosis.
Topics: Adamantane; AIDS-Related Opportunistic Infections; Animals; Anti-Bacterial Agents; Antitubercular Agents; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Drugs, Investigational; Ethylenediamines; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Humans; Isoniazid; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Pyrazinamide; Rifampin; Treatment Refusal; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2007 |
New anti-tuberculosis drugs with novel mechanisms of action.
Topics: Adamantane; Animals; Antitubercular Agents; Diarylquinolines; Drug Design; Drug Resistance, Multiple, Bacterial; Ethylenediamines; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Quinolines; Structure-Activity Relationship; Tuberculosis, Pulmonary | 2008 |
Tuberculosis: clinical trials and new drug regimens.
Topics: Acetamides; Adamantane; Antitubercular Agents; Clinical Trials as Topic; Diarylquinolines; Drug Administration Schedule; Drug Design; Ethylenediamines; Female; Fluoroquinolones; Humans; Levofloxacin; Linezolid; Male; Moxifloxacin; Nitroimidazoles; Oxazoles; Oxazolidinones; Spiro Compounds; Thiazines; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2014 |
Novel drugs against tuberculosis: a clinician's perspective.
Topics: Adamantane; Antitubercular Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diarylquinolines; Drug Therapy, Combination; Ethylenediamines; Extensively Drug-Resistant Tuberculosis; Female; Follow-Up Studies; Humans; Male; Nitroimidazoles; Oxazoles; Oxazolidinones; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2015 |
New and repurposed drugs to treat multidrug- and extensively drug-resistant tuberculosis.
Topics: Antitubercular Agents; Clinical Trials as Topic; Diarylquinolines; Drug Repositioning; Extensively Drug-Resistant Tuberculosis; Humans; Nitroimidazoles; Oxazoles | 2018 |
New drugs to treat difficult tuberculous and nontuberculous mycobacterial pulmonary disease.
Topics: Amikacin; Anti-Bacterial Agents; Clofazimine; Diarylquinolines; Extensively Drug-Resistant Tuberculosis; Humans; Linezolid; Liposomes; Lung Diseases; Microbial Sensitivity Tests; Mycobacterium Infections, Nontuberculous; Nitroimidazoles; Oxazoles | 2019 |
The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis.
Topics: Antitubercular Agents; Diarylquinolines; Drug Therapy, Combination; Humans; Linezolid; Nitroimidazoles; Oxazoles; Periodicals as Topic; Pulmonary Medicine; Societies, Medical; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2019 |
Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid.
Topics: Antitubercular Agents; Clofazimine; Diarylquinolines; Humans; Linezolid; Microbial Sensitivity Tests; Mutation; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Pharmaceutical Preparations; Tuberculosis, Multidrug-Resistant | 2020 |
16 other study(ies) available for oxazoles and pa 824
| Article | Year |
|---|---|
A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.
Topics: Animals; Antitubercular Agents; Bacterial Proteins; Drug Resistance, Microbial; Drug Resistance, Multiple; Guinea Pigs; Lipids; Metronidazole; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Structure-Activity Relationship; Tuberculosis | 2000 |
Synthesis and antitubercular activity of 7-(R)- and 7-(S)-methyl-2-nitro-6-(S)-(4-(trifluoromethoxy)benzyloxy)-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazines, analogues of PA-824.
Topics: Antitubercular Agents; Crystallography, X-Ray; Drug Resistance, Bacterial; Mycobacterium tuberculosis; Nitroimidazoles; Oxazines; Oxazoles; Stereoisomerism; Structure-Activity Relationship | 2008 |
[Some new antitubercular agents].
Topics: Acetamides; Antitubercular Agents; Diarylquinolines; Humans; Linezolid; Nitroimidazoles; Oxazoles; Oxazolidinones; Quinolines | 2008 |
Substrate specificity of the deazaflavin-dependent nitroreductase from Mycobacterium tuberculosis responsible for the bioreductive activation of bicyclic nitroimidazoles.
Topics: Antitubercular Agents; Cloning, Molecular; Flavins; Kinetics; Mycobacterium tuberculosis; Nitric Oxide; Nitroimidazoles; Nitroreductases; Oxazoles; Protein Conformation; Stereoisomerism; Structure-Activity Relationship; Substrate Specificity | 2012 |
In vitro and in vivo activities of the nitroimidazole TBA-354 against Mycobacterium tuberculosis.
Topics: Animals; Antitubercular Agents; Caco-2 Cells; Cell Line, Tumor; Disease Models, Animal; Drug Interactions; Drug Resistance, Bacterial; Female; Humans; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Oxazines; Oxazoles; Tuberculosis | 2015 |
Contribution of the nitroimidazoles PA-824 and TBA-354 to the activity of novel regimens in murine models of tuberculosis.
Topics: Animals; Antitubercular Agents; Clofazimine; Diarylquinolines; Disease Models, Animal; Drug Therapy, Combination; Female; Fluoroquinolones; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Oxazines; Oxazoles; Pyrazinamide; Random Allocation; Tuberculosis | 2015 |
Synthesis and structure-activity relationships for extended side chain analogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824).
Topics: Administration, Oral; Animals; Antitubercular Agents; Biological Availability; Chemistry Techniques, Synthetic; Chronic Disease; Disease Models, Animal; Humans; Male; Mice, Inbred BALB C; Mice, Inbred Strains; Microbial Sensitivity Tests; Microsomes, Liver; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Rats, Sprague-Dawley; Structure-Activity Relationship; Tuberculosis | 2015 |
Contribution of Oxazolidinones to the Efficacy of Novel Regimens Containing Bedaquiline and Pretomanid in a Mouse Model of Tuberculosis.
Topics: Animals; Antitubercular Agents; Bacterial Load; Diarylquinolines; Disease Models, Animal; Drug Administration Schedule; Drug Combinations; Drug Resistance, Multiple, Bacterial; Drug Synergism; Female; Linezolid; Lung; Mice; Mice, Inbred BALB C; Mycobacterium tuberculosis; Nitroimidazoles; Organophosphates; Oxazoles; Oxazolidinones; Pyrazinamide; Time Factors; Treatment Outcome; Tuberculosis, Pulmonary | 2016 |
6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]thiazoles: Facile synthesis and comparative appraisal against tuberculosis and neglected tropical diseases.
Topics: Animals; Antitubercular Agents; Chagas Disease; Disease Models, Animal; Mice; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Structure-Activity Relationship; Thiazoles; Tuberculosis | 2017 |
Biopharmaceutic parameters, pharmacokinetics, transport and CYP-mediated drug interactions of IIIM-017: A novel nitroimidazooxazole analogue with anti-tuberculosis activity.
Topics: Animals; Antitubercular Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Caco-2 Cells; Computer Simulation; Drug Interactions; Humans; Mice, Inbred BALB C; Microsomes, Liver; Nitroimidazoles; Oxazoles | 2017 |
Coenzyme F
Topics: Antitubercular Agents; Bacterial Proteins; Drug Resistance, Bacterial; Glucosephosphate Dehydrogenase; Ligases; Methanobacteriaceae; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Polyglutamic Acid; Recombinant Proteins; Riboflavin; Tetrahydrofolates | 2018 |
Transcriptional profiling of a laboratory and clinical Mycobacterium tuberculosis strain suggests respiratory poisoning upon exposure to delamanid.
Topics: Aerobiosis; Antitubercular Agents; Cell Wall; Gene Expression Profiling; Gene Expression Regulation, Bacterial; Genome; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; RNA, Bacterial; Sequence Analysis, RNA | 2019 |
Predicting nitroimidazole antibiotic resistance mutations in Mycobacterium tuberculosis with protein engineering.
Topics: Antitubercular Agents; Bacterial Proteins; Drug Resistance, Bacterial; Mutation; Mycobacterium tuberculosis; Nitroimidazoles; Nitroreductases; Oxazoles; Polymorphism, Genetic; Protein Engineering | 2020 |
Mutations in
Topics: Animals; Antitubercular Agents; Mice; Mutation; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles | 2020 |
Genetic diversity of candidate loci linked to Mycobacterium tuberculosis resistance to bedaquiline, delamanid and pretomanid.
Topics: Antitubercular Agents; Diarylquinolines; Drug Resistance, Multiple, Bacterial; Humans; Mutation; Mycobacterium smegmatis; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant; Whole Genome Sequencing | 2021 |
Delamanid or pretomanid? A Solomonic judgement!
Topics: Antitubercular Agents; Diarylquinolines; Humans; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant | 2022 |